COMT and cervical cancer: It can also be due to the negative feedback that methylated products of COMT have on CYP1A1 and CYP1B1; this inhibition probably leads to a shift in the estrogen metabolizing pathways, causing proliferative effects on cells, which could contribute to an increase in the risk for cervical cancer.